AZ slows durvalumab's development path in SCCHN

AstraZeneca plc (LSE:AZN; NYSE:AZN) said that due to a changing marketplace, it no longer intends to submit regulatory applications for PD-L1 inhibitor

Read the full 227 word article

User Sign In